MELBOURNE, June 29, 2026, 07:02 AEST
- 4DMedical shares dropped 8.97% to A$4.16 on Friday after CT:VQ landed on Australia’s ARTG register.
- About 12.24 million shares changed hands on Friday, nearly 1.7 times what the stock averaged over the past four sessions.
- StockLight puts 4DMedical’s market cap at A$2.5 billion, or 426.3 times sales.
- ASX cash equities sat in pre-open at the dateline. Regular trade is set to kick off at 09:59:45 Sydney time.
4DMedical Ltd ASX:4DX opens the week with a mixed message for investors. The company got Australian regulatory approval for its CT:VQ lung-imaging software, but the shares dropped after the news. The stock ended Friday at A$4.16, off 8.97%. The S&P/ASX 200 (INDEXASX:XJO) inched up 0.18% to 8,764.2. The index was down 0.73% for the week, ABC said.
Friday’s session saw busy trading with 12.24 million shares changing hands, or 30.1% of the past week’s volume and 1.7 times the average for Monday through Thursday, data from Morningstar via Motley Fool show. 4DMedical ended the day down 8.4% compared to last Friday’s A$4.54 finish.
| Last week | 4DMedical | S&P/ASX 200 |
|---|---|---|
| Friday close/level | A$4.16 | 8,764.2 |
| Friday move | fell 8.97% | up 0.18% |
| Week move | dropped 8.37% | down 0.73% |
| Friday 4DX volume | 12.24 million shares | — |
Sources: Morningstar pricing data from Motley Fool, StockLight, ABC market wrap, plus calculated figures.
The move in price turns attention back to cash conversion. Getting a TGA entry can help a company enter the market, but it doesn’t determine Medicare payments. 4DMedical said it plans to file for Medicare Benefits Schedule reimbursement for CT:VQ with the Medical Services Advisory Committee.
| Valuation marker | 4DMedical | ASX medical devices industry average |
|---|---|---|
| Market value | A$2.5 billion | — |
| Price/sales | 426.3x | 2.3x |
| Price/book | 37.6x | 3.6x |
| 52-week range | A$0.23 to A$7.55 | — |
Source: StockLight.
4DMedical Limited got its “X-ray system, diagnostic, computed tomography, application program software” listed on the TGA’s ARTG on June 25 as a Class IIa device, ARTG ID 528192. The company said in a June 26 ASX statement that CT:VQ is now cleared for commercial rollout in Australia. Therapeutic Goods Administration (TGA)
CT:VQ is software only. The company says it works with standard non-contrast chest CT scans, giving regional ventilation and perfusion data without injections, contrast agents, or nuclear medicine or radiotracers. 4DMedical said Australia has over 74 CT scanners per million people.
Founder and CEO Andreas Fouras said the approval “clears the way” for the company to roll out locally. Fouras also pointed to Australia’s CT scanner density, calling it “one of the most scalable markets we have entered.” U.S. momentum, he said, “continues to build.”
4DMedical said CT:VQ is already in use at Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine and University of Miami. The company said Mayo Clinic is well along in evaluating the tech. 4DMedical called SimonMed Imaging a model for taking the rollout wider across Australia, pointing to the U.S. approach as its reference case.
ASX trading is set to open at 09:59:45 Sydney time. Focus is on whether Friday’s A$4.16 closing level will stick after the break. Market will be watching for updates on site rollout and the MSAC reimbursement process.
